ResultsIQ

ResultsIQ › Latest results › Anthem Biosciences Limited

Anthem Biosciences Limited Q2 FY27 results deck summary

NSE: ANTHEM · BSE: 544449

Results deck of 3 Nov 2026, summarised by AI from the filing.

Management says it is well-positioned to sustain this performance all year, without giving a margin figure.

Key takeaways

  1. Margin outlook Management says it is well-positioned to sustain this performance all year, without giving a margin figure.
  2. H1 revenue H1FY27 revenue from operations was ₹10,123 Mn, below H1FY26's ₹10,914 Mn (-7.2%).

Original filing on BSE

Anthem Biosciences Limited Q2 FY27 results

As filed: Revenue ₹594 cr (+8% year on year), EBITDA ₹271 cr (+24% year on year), PAT ₹211 cr (+22% year on year), EBITDA margin 45.7% (+588 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹418 cr (−23% year on year), EBITDA ₹151 cr (−21% year on year), PAT ₹120 cr (−12% year on year), EBITDA margin 36.0% (+63 bps). Score 18 of 100, Below trend. EBITDA margin rose 63 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 32% from last quarter. Share price after the results: +10.5% in 30 days (Nifty 500: +0.7%).
  • Q4 FY26: Revenue ₹583 cr, EBITDA ₹267 cr, PAT ₹212 cr, EBITDA margin 45.8%. Not scored. No result for the same quarter last year. Share price after the results: +1.4% in 30 days (Nifty 500: +3.0%).
  • Q3 FY26: Revenue ₹417 cr, EBITDA ₹163 cr, PAT ₹112 cr, EBITDA margin 39.1%. Not scored. No result for the same quarter last year. Share price after the results: +4.4% in 29 days (Nifty 500: −4.0%).
  • Q2 FY26: Revenue ₹552 cr, EBITDA ₹225 cr, PAT ₹198 cr, EBITDA margin 40.8%. Not scored. No result for the same quarter last year. Share price after the results: −6.8% in 30 days (Nifty 500: 0.0%).
  • Q1 FY26: Revenue ₹538 cr, EBITDA ₹196 cr, PAT ₹148 cr, EBITDA margin 36.4%. Not scored. No result for the same quarter last year. Share price after the results: +10.4% in 30 days (Nifty 500: +2.2%).

Past price moves after results do not indicate future moves. Not a recommendation.

Anthem Biosciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.